OncoMatch/Clinical Trials/NCT06539182
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Is NCT06539182 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including DZD8586 and DZD8586 for chronic lymphocytic leukemia/small lymphocytic lymphoma.
Treatment: DZD8586 · DZD8586 · DZD8586 — This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: stem cell transplantation
Stem cell transplantation, cell therapy, or gene therapy within 90 days.
Cannot have received: cell therapy
Stem cell transplantation, cell therapy, or gene therapy within 90 days.
Cannot have received: gene therapy
Stem cell transplantation, cell therapy, or gene therapy within 90 days.
Cannot have received: small molecule therapy
Approved small molecule therapy within 5 half-lives
Cannot have received: monoclonal antibody
monoclonal antibodies and antibody-drug conjugates within 28 days
Cannot have received: antibody-drug conjugate
monoclonal antibodies and antibody-drug conjugates within 28 days
Lab requirements
Blood counts
Adequate bone marrow reserve
Kidney function
Adequate organ system functions
Liver function
Adequate organ system functions
Adequate bone marrow reserve and organ system functions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify